Continuous Alcohol Monitoring for Pancreatitis

Status Not yet recruiting

Clinical Trial Summary

The purpose the research is to demonstrate the feasibility of using a transdermal alcohol sensing device (BACtrack Skyn), and to correlate biological and self-reported alcohol measures with the transdermal alcohol measures in patients with a history of pancreatitis. The results from this study will inform tailored, self-directed interventions for reducing alcohol consumption in persons with pancreatitis.

Clinical Trial Description

Alcohol is the leading cause of recurrent acute and chronic pancreatitis, which greatly elevates the risk of pancreatic cancer. Reducing alcohol intake in patients with a history of alcoholic pancreatitis prevents progression of pancreatitis. Provider-based education on alcohol reduction has not translated to sustainable behaviors change, and more effective and scalable interventions are needed. Wearable alcohol sensors can empower patient-directed behavior change through real-time feedback on alcohol levels in the blood. BACtrack Skyn, the winner of NIAAA's Wearable Alcohol Biosensor Challenge, is a validated transdermal alcohol sensor that estimates blood alcohol concentration. In this pilot study, the investigators aim to (a) determine the feasibility and acceptability of using BACtrack Skyn to monitor changes in blood alcohol concentration among patients at risk for pancreatitis, (b) assess correlations between alcohol levels measured with BACtrack Skyn, breathalyzer, patient-reported alcohol consumption, and urine alcohol metabolite levels, (c) explore whether the use of a wearable alcohol sensor results in a decrease in alcohol consumption over a two-week period. Sixteen participants with known history of alcoholic pancreatitis will be assigned to wearing BACtrack Skyn for 2 weeks with the goal of not exceeding a blood alcohol concentration of 0.08%. Patient-reported drinking history, urine will be collected to correlate reported drinking levels and alcohol metabolic levels with the blood alcohol concentration readings in BACtrack Skyn. Findings from this study will be used as preliminary data to support and optimize subsequent grant applications and inform larger, randomized trials. The proposed study aligns closely with the mission of Cedars-Sinai and contributes to the growing body of research focusing on novel technologies for cancer prevention and control, as well as translational studies on alcoholic gastrointestinal diseases. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04350996
Study type	Observational
Source	Cedars-Sinai Medical Center
Contact	Gillian Gresham Gresham, PhD
Phone	410-323-3341
Email	gillian.gresham@cshs.org
Status	Not yet recruiting
Phase
Start date	June 2020
Completion date	June 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05414344` - A Brief Intervention for Alcohol Users With Interpersonal Trauma	N/A
Completed	`NCT05521906` - Evaluation of PRYSHM for LGBTQIA2S+ Youth	N/A
Not yet recruiting	`NCT04786587` - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Withdrawn	`NCT04659278` - Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use	N/A
Not yet recruiting	`NCT03632408` - Hangover and Residual Zopiclone Effect on Spatial Perception	Phase 1
Completed	`NCT02718508` - An e-Parenting Skills Intervention to Decrease Injured Adolescents' Alcohol Use	N/A
Active, not recruiting	`NCT02629679` - Sports, Education and Consumption of Substances in Adolescents	N/A
Completed	`NCT02945371` - Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life	N/A
Completed	`NCT01553136` - Varenicline Treatment of Alcohol Dependence in Smokers	Phase 2
Completed	`NCT01442753` - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth	N/A
Completed	`NCT01081119` - Brief Voluntary Alcohol and Drug Intervention for Middle School Youth	Phase 2
Completed	`NCT04510116` - Adults In The Making Prevention Trial	N/A
Completed	`NCT00289965` - Substance Use Risk Education (SURE) Project	Phase 2
Completed	`NCT00506753` - Motivation and Skills for Delta-9-tetrahydrocannabinol/Ethanol (THC/ETOH+) Teens in Jail	N/A
Recruiting	`NCT05288790` - Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT	Phase 2
Recruiting	`NCT05620849` - Young Adult Education on Alcohol & Health	N/A
Recruiting	`NCT04054466` - Nursing Counseling to the Change of Behavior of Alcohol Consumption in Patients in HAART	N/A
Recruiting	`NCT03588754` - Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?	Phase 2
Recruiting	`NCT06074341` - TeleHealth Resources for IndiVidualizEd Goals (THRIVE) in Alcohol Recovery Study	N/A
Terminated	`NCT04596267` - Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Continuous Alcohol Monitoring for Pancreatitis — CAMP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms